All posts by CAC2

CAC2 Childhood Cancer Community News Digest (February 19-25)

Assorted News from the Last Week: Penn State students have raised more than $16.9 million for pediatric cancer patients in the annual 46-hour dance marathon known as Thon. More than 225 advocates from 32 states participated and shared their stories, asking for congressional support for important legislation and funding for childhood cancer.  CAC2 members, Alliance members, and many others across the country had their voices heard. U.S. Congressman Michael McCaul (R-Texas), along with Ranking Member of Energy and Commerce’s Health Subcommittee Anna Eshoo (D-Calif.) and Representatives Gus Bilirakis (R-Fla.), Lori Trahan (D-Mass.), Michael Burgess (R-Texas), and Nanette Barragán (D-Calif.), introduced [...] Read more

Community News–Childhood Cancer Advocates Support Successful 2024 Action Day!

The Alliance for Childhood Cancer sends its thanks for a fantastic Action Day on February 14.  More than 225 advocates from 32 states participated and shared their stories, asking for congressional support for important legislation and funding for childhood cancer.  CAC2 members, Alliance members, and many others across the country had their voices heard. This year’s asks: Federal Funding for Childhood Cancer Programs We request $30 million to fully fund the Childhood Cancer STAR Reauthorization Act for a 7th year and $50 million to fully fund the Childhood Cancer Data Initiative (CCDI) for a 6th year. Additionally, we urge Congress […]

Read more

CAC2 Childhood Cancer Community News Digest (February 12-18)

Assorted News from the Last Week: A Belgian boy with DIPG has lived seven years after his diagnosis and now at 13 years old, there is no trace of the tumor left.  He was enrolled in the BIOMEDE trial, and from the start responded strongly to the cancer drug everolimus. CAC2 Blog post: A Tribute to Pediatric Cancer Caregivers: Honoring Heroes Research demonstrates the feasibility of linking central cancer registry and pediatric cancer clinical trial consortium data to track patients and describe gaps in clinical trial enrollment. St. Jude Children’s Research Hospital has introduced a simple tool in Latin America called [...] Read more

CAC2 Childhood Cancer Community News Digest (February 5-11)

Assorted News from the Last Week: The National Comprehensive Cancer Network® (NCCN®) published its first ever set of treatment recommendations pertaining to neuroblastoma. Replacing brentuximab vedotin with nivolumab in first-line treatment combined with the chemotherapy regimen AVD improved progression-free survival in pediatric patients with newly diagnosed, advanced-stage classic Hodgkin lymphoma (cHL). Study results confirm that RNA sequencing analysis (RNA-Seq) workflow for clinical diagnosis of molecular subtypes in pediatric B-acute lymphoblastic leukemia (B-ALL) is a feasible method. A new rapid, cost-effective, and accurate ATRT subgrouping assay applicable for clinical use is presented. CAC2 Member ASK Childhood Cancer Foundation helps local 9-year-old [...] Read more

CAC2 Childhood Cancer Community News Digest (January 29-February 4)

Assorted News from the Last Week: Hispanic population appears underrepresented in pediatric cancer trials. Liquid biopsies to monitor therapy success and to predict the recurrence of the tumor in time to take medical countermeasures are being used for the first time in neuroblastoma patients through the MONALISA project. The U.S. Food and Drug Administration (FDA) has issued a public reminder to healthcare providers that PEDMARK (sodium thiosulfate injection) by CAC2 Supporting Organization Fennec Pharmaceuticals is not substitutable with other sodium thiosulfate products as explicitly directed in its prescribing label. World Cancer Day Trends:  The number of new cancer cases globally [...] Read more

CAC2 Childhood Cancer Community News Digest (January 22-28)

Assorted News from the Last Week: A year after an investigation revealed widespread use of a substandard version of asparaginase, the World Health Organization and national drug regulators around the world have come under fire for failing to protect children from the dangerous chemotherapy. The drug tovorafenib may halt the growth of or shrink some childhood brain tumors, according to a clinical trial published in Nature Medicine. Bevacizumab-containing chemotherapy improved responses in pediatric patients with relapsed or refractory, high-risk neuroblastoma. Over 3% of all cancer patients in India are under aged 15 and 4.6% under 20. Childhood cancer has long-term [...] Read more

Action Days: Know Before You Go

Action Days 2024 takes place February 13-14, 2024, in Washington, D.C. Childhood cancer advocates will have another opportunity to speak with members of Congress to gain support for legislation pending in both the House and Senate. To help prepare CAC2 members before we visit Capitol Hill, we hosted an information webinar with Rosie Abbott, Head of Government Relations at St. Baldrick's, and the Alliance for Childhood Cancer.  CAC2 Board Member Susannah Koontz began the webinar with a review of the legislative accomplishments for our community in 2023. Even if you can't attend, the information is helpful in understanding the issues [...] Read more

CAC2 Childhood Cancer Community News Digest (January 15-21)

Assorted News from the Last Week: The Coalition Against Childhood Cancer (CAC2) takes great pride in introducing its groundbreaking CAC2 Survivorship Toolkit. Training that increases self-confidence, reduces personal limitations, and decreases perceived barriers to fertility preservation (FP) care among oncology nurses can improve their ability to counsel patients about fertility preservation. Scientists at La Jolla Institute for Immunology (LJI) have published an in-depth study into how the immune system’s T cells target pediatric brain tumors. Their research suggests that a small number of pediatric brain tumor patients already have cancer-fighting T cells within their tumors. High-deductible health plans erect ‘barriers’ [...] Read more

CAC2 Childhood Cancer Community News Digest (January 8-14)

Assorted News from the Last Week: The Coalition Against Childhood Cancer (CAC2) takes great pride in introducing its groundbreaking CAC2 Survivorship Toolkit. Scientists found that two common biomarkers could predict cardiomyopathy that is otherwise undetected by conventional screenings in childhood cancer survivors. Michael Strahan's 19-year-old daughter Isabella is battling a malignant brain tumor known as medulloblastoma, the "Good Morning America" co-anchor and his daughter shared Thursday. Cancer specialists remain baffled about the cause(s) of an alarming increase in cancer among younger adults. (gated) The use of low-dose carvedilol did not significantly improve certain cardiac measures of heart failure risk in [...] Read more

Empowering Lives After Cancer: Introducing the Coalition Against Childhood Cancer’s CAC2 Survivorship Toolkit

In the continually evolving landscape of cancer care, the survivorship phase stands as a pivotal and unique challenge. Recognizing the significance of this critical juncture, the Coalition Against Childhood Cancer (CAC2) takes great pride in introducing its groundbreaking CAC2 Survivorship Toolkit. This meticulously curated online resource, boasting over 500 resources and publications, is designed to meet the diverse needs of childhood, adolescent, and young adult (AYA) cancer survivors and their families throughout the lifespan. Let’s delve into the distinguishing features that set the CAC2 Survivorship Toolkit apart as a vital support resource for individuals navigating the intricate journey of life […]

Read more